olivLaw · US equity research
Novavax, Inc. NVAX
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
Novavax develops vaccines based on recombinant protein nanoparticles and its proprietary Matrix-M adjuvant, and its business has shifted from direct sales of its COVID-19 vaccine toward partnerships that earn licensing revenue and milestones. Total revenue for the second quarter of 2026 was 57 million USD, down from the prior year, and the company now relies on partners such as Sanofi and Pfizer.
At the close of 04 Nov 2026, Novavax, Inc. (NVAX) stock was 10.65 USD (+10.02% on the day), with market capitalisation 1.8 bn USD, beta 1.52, 52-week range 6.22–12.82 USD. Latest reported quarter (Q2 2026): revenue of 56.7 m USD (−76.3% YoY), net income of -53.4 m USD (−150.1% YoY), diluted EPS -0.32 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 50.9
- neutral
- Bollinger (20, 2)
- 8.62 – 13.29
- in the lower half of the band · %B 0.44 · band width 42.6%
- SMA 50 / 200
- 10.51 / 9.32
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- -0.22 / -0.09
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −15.2% | −1.1% | −14.1 pp | — |
| 3 months | +39.0% | −0.5% | +39.5 pp | — |
| 6 months | +13.8% | +4.4% | +9.4 pp | — |
| Year to date | +58.5% | +12.3% | +46.2 pp | — |
| 1 year | +41.8% | +13.5% | +28.3 pp | +9.1% |
| 3 years | +50.8% | +76.4% | −25.6 pp | +16.5% |
| 5 years | −93.3% | +63.7% | −157.0 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 84.5 m | 88.3 m | 666.7 m | 239.2 m | 70.4 m | 147.1 m | 139.5 m | 56.7 m |
| Cost of revenue | 60.6 m | 36.7 m | 14.1 m | 15.3 m | 21.5 m | 22.1 m | 30.7 m | 14.2 m |
| Research & development | 87.2 m | 104.4 m | 88.9 m | 79.2 m | 98.3 m | 75.9 m | 95.5 m | 70.7 m |
| SG&A | 70.7 m | 78.3 m | 48.1 m | 43.6 m | 31.7 m | 34.1 m | 28.8 m | 26.7 m |
| Operating income | -134.0 m | -131.1 m | 515.5 m | 101.1 m | -178.0 m | 14.2 m | -15.4 m | -54.9 m |
| Depreciation & amortisation | 12.7 m ≈ | 12.0 m | 8.3 m | 7.6 m ≈ | 6.6 m ≈ | 5.5 m | 3.1 m | 3.1 m ≈ |
| Interest expense | 4.2 m | 7.6 m | 5.7 m | 5.5 m | 5.5 m | 5.8 m | 4.9 m | 5.7 m |
| Pre-tax income | -122.3 m | -73.6 m | 519.8 m | 107.5 m | -203.0 m | 17.9 m | -8.5 m | -51.7 m |
| Income tax | -1.0 m | 7.4 m | 1.2 m | 946.0 k | -657.0 k | 376.0 k | 985.0 k | 1.7 m |
| Net income | -121.3 m | -81.0 m | 518.6 m | 106.5 m | -202.4 m | 17.5 m | -9.5 m | -53.4 m |
| Diluted EPS | -0.76 | -0.51 ≈ | 2.93 | 0.62 | -1.25 | 0.09 ≈ | -0.06 | -0.32 |
| Operating cash flow | -144.8 m ≈ | -173.2 m | -185.5 m | -127.5 m ≈ | 107.8 m ≈ | -39.5 m | -32.4 m | -72.8 m ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 34.3 m | 18.7 m | 475.6 m | 1.1 bn | 2.0 bn | 983.7 m | 682.2 m | 1.1 bn |
| Revenue YoY | +10.0% | −45.6% | +2,448.5% | +141.0% | +72.9% | −50.4% | −30.7% | +64.7% |
| Net income | -184.7 m | -132.7 m | -418.3 m | -1.7 bn | -657.9 m | -545.1 m | -187.5 m | 440.3 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | -5.51 | -7.27 | -23.44 | -8.42 | -5.41 | -1.23 | 2.58 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -538.8% | -711.0% | -87.9% | -152.1% | -33.2% | -55.4% | -27.5% | 39.2% |
| Free cash flow | -186.2 m | -138.5 m | -97.2 m | 265.5 m | unavailable | unavailable | unavailable | unavailable |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 240.6 m USD
- Financial debt
- 244.2 m USD
- Net debt
- 3.6 m USD
- Equity
- -127.8 m USD
- Total assets
- 1.2 bn USD
- Debt / equity
- unavailable
- Current ratio
- 2.13x
- ROE
- unavailable
- ROA
- 32.2%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 475.6 m | 1.1 bn | 2.0 bn | 983.7 m | 682.2 m | 1.1 bn | SEC (XBRL)· 26 Feb 2026verified |
| Cost of revenue | 0 | 0 | 902.6 m | 343.8 m | 202.7 m | 73.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Gross profit | 475.6 m ≈ | 1.1 bn ≈ | 1.1 bn ≈ | 639.9 m ≈ | 479.4 m ≈ | 1.1 bn ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Research & development | 747.0 m | 2.5 bn | 1.2 bn | 737.5 m | 391.2 m | 342.3 m | SEC (XBRL)· 26 Feb 2026verified |
| SG&A | — | — | 488.7 m | 468.9 m | 337.2 m | 157.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Operating income | -416.7 m | -1.7 bn | -644.7 m | -566.5 m | -248.9 m | 452.8 m | SEC (XBRL)· 26 Feb 2026verified |
| Depreciation & amortisation | 4.3 m | 13.0 m | 29.0 m | 41.0 m | 48.0 m | 28.0 m | SEC (XBRL)· 26 Feb 2026verified |
| EBITDA | -412.4 m ≈ | -1.7 bn ≈ | -615.7 m ≈ | -525.5 m ≈ | -200.9 m ≈ | 480.8 m ≈ | SEC (XBRL)· 26 Feb 2026derived |
| Interest expense | 15.1 m | 21.1 m | 19.9 m | 14.4 m | 20.1 m | 22.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Pre-tax income | -418.3 m | -1.7 bn | -653.6 m | -543.0 m | -176.6 m | 442.2 m | SEC (XBRL)· 26 Feb 2026verified |
| Income tax | 0 | 29.2 m | 4.3 m | 2.0 m | 10.9 m | 1.9 m | SEC (XBRL)· 26 Feb 2026verified |
| Net income | -418.3 m | -1.7 bn | -657.9 m | -545.1 m | -187.5 m | 440.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Diluted EPS | -7.27 | -23.44 | -8.42 | -5.41 | -1.23 | 2.58 | SEC (XBRL)· 26 Feb 2026verified |
| Weighted average diluted shares | 57.6 m | 74.4 m | 78.2 m | 100.8 m | 152.2 m | 173.1 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 553.4 m | 1.5 bn | 1.3 bn | 568.5 m | 530.2 m | 240.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Inventories | — | 8.9 m | 36.7 m | 41.7 m | 8.7 m | 11.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Current assets | 1.2 bn | 2.2 bn | 1.7 bn | 1.1 bn | 1.1 bn | 978.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Property, plant & equipment, net | 180.0 m | 225.7 m | 294.2 m | 305.8 m | 138.4 m | 44.8 m | SEC (XBRL)· 26 Feb 2026verified |
| Goodwill | 135.4 m | 131.5 m | 126.3 m | 127.5 m | 107.5 m | 113.5 m | SEC (XBRL)· 26 Feb 2026verified |
| Intangibles (excl. goodwill) | 5.7 m | 4.8 m | — | — | — | — | SEC (XBRL)· 01 Mar 2022verified |
| Total assets | 1.6 bn | 2.6 bn | 2.3 bn | 1.8 bn | 1.6 bn | 1.2 bn | SEC (XBRL)· 26 Feb 2026verified |
| Accounts payable | 54.3 m | 127.1 m | 216.5 m | 132.6 m | 41.6 m | 24.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Long-term debt | — | — | — | — | — | 244.2 m | SEC (XBRL)· 06 May 2026verified |
| Current liabilities | 579.7 m | 2.4 bn | 2.5 bn | 1.6 bn | 1.2 bn | 460.0 m | SEC (XBRL)· 26 Feb 2026verified |
| Total liabilities | 955.3 m | 2.9 bn | 2.9 bn | 2.5 bn | 2.2 bn | 1.3 bn | SEC (XBRL)· 26 Feb 2026verified |
| Equity | 627.2 m † | -351.7 m † | -634.1 m † | -716.9 m † | -623.8 m † | -127.8 m † | SEC (XBRL)· 26 Feb 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -42.5 m | 322.9 m | -415.9 m | -714.0 m | -87.3 m | -244.6 m | SEC (XBRL)· 26 Feb 2026verified |
| Capex | 54.6 m | 57.5 m | — | — | — | — | SEC (XBRL)· 01 Mar 2022verified |
| Free cash flow | -97.2 m ≈ | 265.5 m ≈ | — | — | — | — | SEC (XBRL)· 01 Mar 2022derived |
| Investing cash flow | -377.8 m | 100.2 m | -93.0 m | -58.8 m | -204.0 m | -78.3 m | SEC (XBRL)· 26 Feb 2026verified |
| Financing cash flow | 984.8 m | 461.7 m | 325.0 m | 4.5 m | 260.6 m | 27.7 m | SEC (XBRL)· 26 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 25.0% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.8 bn USD
Key indicators
Coverage and freshness
Score by group
25% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the input exists, but its latest figure is far older than the latest reported period: not used
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -59.9% | 58 (vs peers) | 25% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -17.2% | 0 (on a fixed band) | 33% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -10.7x | 0 (on a fixed band) | 25% |
| Current ratio · Balance sheet | 2.3x | 100 (on a fixed band) | 17% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial58/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
NOVAVAX INC (NVAX). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 1.1 bn USD in 2025; YoY growth 64.7%; net margin -59.9%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 25.0% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 2.3x
What contradicts it
- Revenue CAGR 3Y: -17.2%
- Interest coverage: -10.7x
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 258.8 bn | 27.7 | 78.4% | 24.1% | +10.0% | +39% / +77% |
| GILDGilead Sciences, Inc. | 216.4 bn | — | -22.3% | -12.5% | +2.4% | +39% / +128% |
| MRNAModerna, Inc. | 103.2 bn | — | -39.0% | -141.4% | −39.9% | +895% / +233% |
| ARGXArgenx Se | 57.6 bn | 47.6 | 20.2% | — | +254.4% | +2% / +107% |
| RVMDRevolution Medicines, Inc. | 43.2 bn | — | -93.6% | -946.8% | unavailable | +157% / +756% |
| BIIBBiogen Inc. | 37.6 bn | 108.8 | 1.9% | 3.4% | +2.2% | +40% / +9% |
| EXELExelixis, Inc. | 17.8 bn | 21.7 | 44.3% | 35.5% | +7.0% | +65% / +234% |
| NBIXNeurocrine Biosciences, Inc. | 16.8 bn | 24.6 | 20.4% | 19.0% | +21.4% | +9% / +42% |
| HALOHalozyme Therapeutics, Inc. | 14.8 bn | 38.4 | 173.7% | 24.9% | +37.6% | +83% / +238% |
| KYMRKymera Therapeutics, Inc. | 11.6 bn | — | -27.3% | -341.8% | −16.7% | +101% / +556% |
| RGENRepligen Corp | 11.4 bn | — | -0.6% | -1.5% | +16.4% | +4% / +13% |
| QGENQiagen N.V. | 11.0 bn | 26.2 | 11.6% | 20.3% | +5.7% | +6% / +20% |
| KRYSKrystal Biotech, Inc. | 9.2 bn | 42.2 | 17.5% | 47.9% | +33.9% | +43% / +198% |
| SCNIScinai Immunotherapeutics Ltd. | 6.2 bn | — | -91.9% | -633.6% | +99.2% | −96% / −99% |
| DNLIDenali Therapeutics Inc. | 3.4 bn | — | -33.9% | -1,470.5% | unavailable | +8% / +13% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.1 bn | — | — | -37.4% | +94.1% | +15% / +40% |
| VIRVir Biotechnology, Inc. | 2.0 bn | — | -21.8% | -61.0% | −7.6% | +83% / +24% |
| NVAXNovavax Inc | 1.8 bn | — | — | -59.9% | +64.7% | +42% / +51% |
| EVAXEvaxion A | 1.2 bn | — | -100.2% | -102.4% | +125.1% | −50% / −93% |
| DNAGinkgo Bioworks Holdings, Inc. | 742.2 m | — | -56.3% | -260.0% | −25.1% | +26% / −77% |
| ATYRaTYR PHARMA INC | 606.2 m | — | -98.4% | -32,003.7% | −19.1% | +691% / +375% |
| ALLOAllogene Therapeutics, Inc. | 411.1 m | — | -42.4% | -3,566.7% | −100.0% | −18% / −49% |
| CCCCC4 Therapeutics, Inc. | 383.8 m | — | -48.1% | -289.4% | +1.0% | +15% / +91% |
| XFORX4 Pharmaceuticals, Inc | 330.8 m | — | -80.3% | -813.3% | +150.0% | −11% / −86% |
| IPSCCentury Therapeutics, Inc. | 302.4 m | — | -49.7% | -100.6% | +1,556.8% | +206% / +22% |
1- and 3-year price returns: for NVAX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Novavax develops vaccines based on recombinant protein nanoparticles and its proprietary Matrix-M adjuvant, and its business has shifted from direct sales of its COVID-19 vaccine toward partnerships that earn licensing revenue and milestones. Total revenue for the second quarter of 2026 was 57 million USD 3, down from the prior year, and the company now relies on partners such as Sanofi and Pfizer.
SWOT
Strengths
- The proprietary Matrix-M adjuvant technology is a distinctive asset that can reduce the amount of antigen needed and has been licensed to several partners 1.
- Partnership agreements generate upfront payments, milestones and royalties, providing revenue without extensive own manufacturing 13.
- The company has reduced expenses and kept a cash position it considers sufficient for the near term, according to second quarter results 3.
Weaknesses
- Revenue is volatile and depends heavily on milestones and partner payments, which makes results hard to forecast 13.
- The company has recorded losses in several years and carries a large accumulated deficit, which limits financial flexibility 1.
- Direct COVID-19 vaccine sales have fallen, and commercialization has largely moved to Sanofi, reducing control over the market 3.
Opportunities
- The COVID-influenza combination and pandemic influenza programs could generate significant milestones if partners reach regulatory stages 3.
- Interest in Matrix-M in oncology and other infectious diseases could open new licenses if partner evaluations reach advanced stages 13.
- The C. difficile candidate could enter the clinic from 2027, which could create a new high-value proprietary program 3.
Threats
- Demand for COVID-19 vaccines remains seasonal and uncertain, and changes in health policy could reduce sales 1.
- The company depends on third parties for manufacturing and distribution, and supplier delays could affect deliveries and related payments 1.
- Cancellation or renegotiation of advance purchase agreements could force the company to refund advance payments, as happened with certain countries 1.
Risks
- Recurring losseshigh
The company has reported losses over several consecutive years, and future profitability is not assured. If partnership revenue does not grow, losses could persist 13.
- Funding needhigh
The company says it does not yet generate enough revenue to cover its operations and may need additional capital. Share issuances could dilute current shareholders 1.
- Dependence on Sanofihigh
A large share of revenue and commercialization plans depends on Sanofi. If the partner delays regulatory stages or decides to scale back programs, revenue could decline 13.
- Regulatory riskmedium
Approval processes are lengthy and uncertain, and a negative decision could delay or stop product launches 1.
- Supplier dependencemedium
The company relies on third parties for manufacturing, co-formulation and filling, and disruptions at these suppliers could affect deliveries 1.
Investment thesis
What would need to be true (bull case)
- If partners advance programs using Matrix-M, milestone and royalty revenue could grow significantly from current levels. The Pfizer agreement and interest in oncology suggest the technology has applications beyond existing vaccines 13.
- Cost reductions and the shift of commercialization to Sanofi could improve operating margins in coming periods 3.
- The C. difficile candidate and preclinical programs could provide a high-value proprietary portfolio if clinical data prove favorable 1.
What would break the thesis
- Revenue in the second quarter of 2026 fell sharply from the prior year, and the company relies on irregular milestones that can be delayed 3.
- The company could remain loss-making and need external funding, which could dilute shareholders 1.
- Dependence on a single major partner and on seasonal COVID-19 vaccine markets could limit predictable growth 13.
What to watch
- Delivery against adjusted total revenue guidance and recognition of partner-related amountsQ3 2026
- Start of the Sanofi Phase 3 COVID-influenza combination trial, which would trigger a 125 million USD milestone2026
- Completion of the Nuvaxovid manufacturing technology transfer to Sanofi, with a 75 million USD milestonemid-2027
- Entry of the C. difficile candidate into the clinic2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Novavax, Inc. develops vaccines and uses its own recombinant nanoparticle technology and the Matrix-M™ adjuvant, which it applies in its COVID-19 vaccine Nuvaxovid™ and in the R21/Matrix-M™ malaria vaccine 1. The company pursues a strategy of partnering its adjuvant and research assets while keeping a lean operating model 1. According to its filings, it reported net income of 440.3 million USD for 2025 1, after losses in earlier years, and an accumulated deficit of 4.6 billion USD at December 31, 2025 1.
Sanofi has been the main recent source of revenue: it took over the transfer of the Nuvaxovid™ marketing authorization and leads commercialization in several markets 1. The company receives milestones tied to partnership stages, and in early 2026 it signed a license agreement with Pfizer for use of Matrix-M™ 1. Product sales in the second quarter of 2026 were 19 million USD, higher than the prior year 3.
Over the longer term, Novavax focuses on programs in its internal pipeline, including a COVID-influenza combination vaccine and a stand-alone influenza vaccine, and a C. difficile vaccine candidate that could enter the clinic as early as 2027 13. The company has shifted its emphasis toward collaborations and a small number of programs with potentially high value.
Segments
Partnerships and licenses
This is the main revenue segment and includes upfront payments, milestones and royalties from agreements with Sanofi, Pfizer, Takeda and Serum Institute. In the second quarter of 2026, licensing, royalties and other revenue was 38 million USD 3.
Product sales and supply
This segment covers sales of Matrix-M adjuvant and finished product to license partners, as well as direct sales of Nuvaxovid. For 2026, the company expects Nuvaxovid product sales between 35 and 45 million USD 3.
Research and development
The company invests in its own candidates and preclinical programs, and part of its research costs is reimbursed by partners. For 2026, combined R&D and SG&A expenses are guided between 370 and 410 million USD, and the non-GAAP figure after reimbursements between 310 and 340 million USD 3.
Market context
The adjuvant vaccine market is dominated by a small number of large players, and Novavax positions itself as a technology supplier to other manufacturers. Malaria remains a major public health problem, with an estimated 263 million cases in 2023 worldwide 1, and the R21 vaccine was available in 24 countries as of February 2026 1.
The COVID-19 and influenza vaccine market has become smaller and more seasonal, and demand depends on health recommendations and patient behavior. For Novavax, future financial results could depend on how quickly partners expand their use of the adjuvant in new programs.
Trends
- Loss of COVID-19 revenueheadwind
Quarterly revenue fell sharply from the prior year, reflecting the absence of authorization milestones that were received in 2025 3. If sales of the COVID-19 vaccine remain low, the company could stay dependent on partner payments.
- Wider use of Matrix-Mtailwind
Several partners are evaluating the adjuvant in vaccine programs and in oncology, and the Pfizer agreement signals commercial interest 13. If these programs advance, licensing and royalty revenue could grow.
- Lower operating costsmixed
The company has reduced research and general administrative expenses under a cost reduction program 3. This can limit losses but could also reduce the capacity to fund new programs.
- Reliance on external fundingheadwind
The company says it does not generate enough revenue to fully fund its operations and may need additional funds through partnerships, equity or debt offerings, or other sources 1. If access to capital becomes harder, development plans could be delayed.
Competitive position
Novavax competes with large pharmaceutical companies that have far greater resources and commercial experience, according to its own annual report 1. Competition appears both in COVID-19 and influenza vaccines and in adjuvant technology, where the company tries to stand out through its antigen-sparing effect.
The company notes that many competitors have significantly greater resources, which could affect the commercial opportunities of Novavax and its licensed partners 1. In combination COVID-influenza vaccines, Sanofi is both a partner and a potential direct competitor.
- SanofiSNY
License partner for Nuvaxovid and for the combination COVID-influenza programs, leads commercialization in several markets and is also a potential competitor in the combination vaccine segment.
- PfizerPFE
Large pharmaceutical company that signed a license agreement with Novavax for the Matrix-M adjuvant and is active in the vaccine market.
- Serum Institute of India
Manufacturer of the R21 malaria vaccine and a partner of Novavax, which also provides production capacity.
- Takeda
License partner that achieved a market share in Japan for Nuvaxovid under its agreements with Novavax.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?Yahoo Finance — News · 01 Sept 2026 · EN
- Novavax Stock Pulls Back After Milestone Vaccine SuccessYahoo Finance — News · 26 Aug 2026 · EN
The latest news item in our archive is from 01 Sept 2026; the newest SEC filing is from 29 Oct 2026. The press archive comes from the RSS feeds we follow and does not necessarily cover the latest event — the filings alongside do.
SEC filings
- Current report29 Oct 2026Regulation FD disclosure · Other events · Financial statements and exhibits
- Current report06 Aug 2026Results of operations · Financial statements and exhibits
- Quarterly report06 Aug 2026
- Current report23 Jun 2026Shareholder vote
- Current report06 May 2026Results of operations · Financial statements and exhibits
- Quarterly report06 May 2026
- Proxy statement27 Apr 2026
- Current report26 Feb 2026Results of operations · Financial statements and exhibits
- Annual report26 Feb 2026
- Current report20 Jan 2026Material agreement
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Novavax, Inc. · 26 Feb 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Novavax, Inc. · 06 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Novavax, Inc. · 06 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.